Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity

1. A method of treating a condition selected from the group consisting of headache, neuropathic pain, chronic inflammatory pain, visceral pain, neuroinflammation, medication-induced hyperalgesia and/or allodynia, acute pain, chronic pain, and bone cancer pain in a mammal, wherein said method comprises administering an effective amount of a compound

wherein,

Q is S—(CHR 6 ) 1 ;

R 1 and each R 6 is, independently, H, optionally substituted C 1-6 alkyl, optionally substituted C 1-4 alkaryl, optionally substituted C 1-4 alkheterocyclyl, optionally substituted C 2-9 heterocyclyl, optionally substituted C 3-8 cycloalkyl, optionally substituted C 1-4 alkcycloalkyl, or —(CR 1A R 1B ) n NR 1C R 1D ;

R 1A and R 1B are, independently, H, hydroxy, halo, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkoxy, optionally substituted C 1-4 alkcycloalkyl, optionally substituted C 1-4 alkaryl, optionally substituted C 1-4 alkheterocyclyl, optionally substituted C 1-4 alkheteroaryl, optionally substituted C 3-8 cycloalkyl, or optionally substituted C 2-9 heterocyclyl, or R 1A and R 1B combine to form ═O;

R 1C and R 1D are, independently, H, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkoxy, optionally substituted C 1-4 alkcycloalkyl, optionally substituted C 1-4 alkaryl, optionally substituted C 1-4 alkheterocyclyl, optionally substituted C 1-4 alkheteroaryl, optionally substituted C 3-8 cycloalkyl, optionally substituted C 2-9 heterocyclyl, or an N-protecting group selected from the group consisting of formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, alaninyl, leucinyl, phenylalaninyl, benzenesulfonyl, p-toluenesulfonyl, benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenylyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxy carbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxy carbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl, benzyl, triphenylmethyl, benzyloxymethyl, and trimethylsilyl, or R 1C and R 1D combine to form an optionally substituted C 2-9 heterocyclyl;

n is an integer between 1-6;

each of R 2 and R 3 is, independently, H, hal, optionally substituted C 1-6 alkyl, optionally substituted C 6-10 aryl, optionally substituted C 1-6 alkaryl, optionally substituted C 2-9 heterocyclyl, hydroxy, optionally substituted C 1-6 alkoxy, optionally substituted C 1-6 thioalkoxy, (CH 2 ) r2 NHC(NH)R 2A , or (CH 2 ) r2 NHC(S)NHR 2B , or optionally substituted C 1-4 alkheterocyclyl,

wherein r2 is an integer from 0 to 2, R 2A is optionally substituted C 1-6 alkyl, optionally substituted C 6-10 aryl, optionally substituted C 1-4 alkaryl, optionally substituted C 2-9 heterocyclyl, optionally substituted C 1-4 alkheterocyclyl, optionally substituted C 1-6 thioalkoxy, optionally substituted C 1-4 thioalkaryl, optionally substituted aryloyl, optionally substituted C 1-4 thioalkheterocyclyl, or; and

R 2B is optionally substituted C 1-4 alkaryl, optionally substituted C 2-9 heterocyclyl, substituted C 1-4 alkheterocyclyl, optionally substituted C 1-6 thioalkoxy, optionally substituted C 1-4 thioalkaryl, optionally substituted aryloyl, optionally substituted C 1-4 thioalkheterocyclyl, or optionally substituted amino; and

each of R 4 and R 5 is independently H, hal, (CH 2 ) r2 NHC(NH)R 2A , or (CH 2 ) r2 NHC(S)NHR 2B ;

wherein Y 1 and Y 2 are each H, or Y 1 and Y 2 together are ═O, or Y 1 and Y 2 are independently H, optionally substituted C 1-6 alkyl, optionally substituted C 6-10 aryl, optionally substituted C 1-6 alkaryl, optionally substituted C 2-9 heterocyclyl, hydroxy, optionally substituted C 1-6 alkoxy, optionally substituted C 1-6 thioalkoxy, or optionally substituted C 1-4 alkheterocyclyl;

wherein one and only one of R 2 , R 3 , R 4 , and R 5 is (CH 2 ) r2 NHC(NH)R 2A or (CH 2 ) r2 NHC(S)NHR 2B ;

or a pharmaceutically acceptable salt thereof to said mammal.

2. The method of claim 1 , wherein said mammal is a human.

3. The method of claim 1 , wherein said headache is migraine headache (with or without aura), chronic tension type headache (CTTH), migraine with allodynia, medication overuse headache, cluster headache, chronic headache, or transformed migraine.

4. The method of claim 1 , wherein said headache is a headache with central sensitization.

5. The method of claim 1 , wherein said chronic pain has components of central sensitization.

6. The method of claim 1 , wherein said chronic pain is neuropathic pain.

7. The method of claim 1 , wherein

R 1 and each R 6 is, independently, H, optionally substituted C 1-6 alkyl, optionally substituted C 1-4 alkaryl, optionally substituted C 1-4 alkheterocyclyl, or optionally substituted C 2-9 heterocyclyl.

8. The method of claim 1 , wherein R 2 , R 3 , R 4 , or R 5 has the formula:

9. The method of claim 8 , wherein R 2A has the formula:

and

each of X 1 , X 2 , X 4 , and X 5 is independently selected from O, S, NR 7 , N, or CR 8 ; X 3 is selected from N or C;

R 7 is H or optionally substituted C 1-6 alkyl;

R 8 is H, hal, optionally substituted C 1-6 alkyl, hydroxy, optionally substituted C 1-6 alkoxy, or optionally substituted C 1-6 thioalkoxy,

wherein at least one of X 1 , X 2 , X 4 , and X 5 is not CR 8 .

10. The method of claim 9 , wherein R 2A has the formula:

and

each of X 1 and X 2 is independently selected from O, S, NH, N, or CH; and

wherein at least one of X 1 and X 2 is not CH.

11. The method of claim 1 , wherein said compound has a structure selected from

and

wherein one of R 4 and R 5 has the following structure:

wherein X 2 is O or S.

12. The method of claim 1 , wherein Y 1 and Y 2 are each H or together are ═O.

13. The method of claim 1 , wherein R 1 is optionally substituted C 1-6 alkyl, optionally substituted C 2-9 heterocyclyl, or optionally substituted C 1-4 alkheterocyclyl.

14. The method of claim 13 , wherein R 1 is optionally substituted aminoC 1-6 alkyl or optionally substituted C 1-4 alkheterocyclyl, wherein said heterocyclyl is a 5- or 6-membered cyclic amine.

15. The method of claim 14 , wherein said cyclic amine is substituted with a carboxyl, C 1-6 alkoxycarbonyl, or carbamoyl group.

16. The method of claim 13 , wherein said heterocyclyl is optionally substituted pyrrolidinyl or optionally substituted piperidinyl.

17. The method of claim 16 , wherein R 1 is

wherein R 9 is H, optionally substituted C 1-6 alkyl, or optionally substituted C 1-4 alkaryl.

18. The method of claim 1 , wherein R 1 is an optionally substituted C 3 -C 8 cycloalkyl.

19. The method of claim 18 , wherein said C 3 -C 8 cycloalkyl is substituted by an amino.

20. The method of claim 1 , wherein R 1 is —(CR 1A R 1B ) n NR 1C R 1D .

21. The method of claim 20 , wherein R 1A and R 1B are each H, and n is 2 or 3.

22. The method of claim 20 , wherein R 1C is H, and R 1D is —CH 3 , —CH 2 CH 3 , —(CH 2 ) 2 OH, or —CH 2 CO 2 H; or R 1C and R 1D combine to form optionally substituted pyrrolidinyl or optionally substituted piperidinyl.

23. The method of claim 20 , wherein R 1 is —CH 2 CH 2 N(CH 3 ) 2 or —CH 2 CH 2 NHCH 3 .

24. The method of claim 1 , wherein one of R 4 or R 5 is H or F.

25. A method of treating a condition selected from the group consisting of headache, neuropathic pain, chronic inflammatory pain, visceral pain, neuroinflammation, medication-induced hyperalgesia and/or allodynia, acute pain, chronic pain, and bone cancer pain in a mammal, wherein said method comprises administering an effective amount of the compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof to said mammal.

26. The method of claim 25 , wherein said headache is migraine headache (with or without aura), chronic tension type headache (CTTH), migraine with allodynia, medication overuse headache, cluster headache, chronic headache, or transformed migraine.